CN101077338B - Nano lanthanum carbonate and orally disintegrating tablet and preparation method - Google Patents
Nano lanthanum carbonate and orally disintegrating tablet and preparation method Download PDFInfo
- Publication number
- CN101077338B CN101077338B CN2006100138360A CN200610013836A CN101077338B CN 101077338 B CN101077338 B CN 101077338B CN 2006100138360 A CN2006100138360 A CN 2006100138360A CN 200610013836 A CN200610013836 A CN 200610013836A CN 101077338 B CN101077338 B CN 101077338B
- Authority
- CN
- China
- Prior art keywords
- parts
- lanthanum
- orally disintegrating
- carbonate
- disintegrating tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910017569 La2(CO3)3 Inorganic materials 0.000 title claims abstract description 50
- 229960001633 lanthanum carbonate Drugs 0.000 title claims abstract description 50
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 title claims abstract description 35
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 239000003826 tablet Substances 0.000 claims abstract description 22
- -1 glidants Substances 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 239000011230 binding agent Substances 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000000945 filler Substances 0.000 claims abstract description 10
- 239000000796 flavoring agent Substances 0.000 claims abstract description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 9
- 239000007884 disintegrant Substances 0.000 claims abstract description 7
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 50
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
- 239000002159 nanocrystal Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000741 silica gel Substances 0.000 claims description 11
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000001099 ammonium carbonate Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 150000002604 lanthanum compounds Chemical class 0.000 claims description 4
- JLRJWBUSTKIQQH-UHFFFAOYSA-K lanthanum(3+);triacetate Chemical compound [La+3].CC([O-])=O.CC([O-])=O.CC([O-])=O JLRJWBUSTKIQQH-UHFFFAOYSA-K 0.000 claims description 4
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 claims description 4
- VQEHIYWBGOJJDM-UHFFFAOYSA-H lanthanum(3+);trisulfate Chemical compound [La+3].[La+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VQEHIYWBGOJJDM-UHFFFAOYSA-H 0.000 claims description 4
- 229940010454 licorice Drugs 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 230000006911 nucleation Effects 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- OXHNIMPTBAKYRS-UHFFFAOYSA-H lanthanum(3+);oxalate Chemical compound [La+3].[La+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O OXHNIMPTBAKYRS-UHFFFAOYSA-H 0.000 claims description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 235000019477 peppermint oil Nutrition 0.000 claims description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical group [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 claims 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 7
- 230000006835 compression Effects 0.000 abstract description 4
- 238000007906 compression Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 12
- 239000013049 sediment Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- 201000005991 hyperphosphatemia Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940020428 renagel Drugs 0.000 description 3
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 229910052746 lanthanum Inorganic materials 0.000 description 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 2
- 229910002055 micronized silica Inorganic materials 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- URRHWTYOQNLUKY-UHFFFAOYSA-N [AlH3].[P] Chemical compound [AlH3].[P] URRHWTYOQNLUKY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002603 lanthanum Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000025061 parathyroid hyperplasia Diseases 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明为纳米碳酸镧口腔崩解片及制备方法。采用干法压片将主药和辅料等在40-80℃下干燥2-4小时,过100目筛,然后压片得到口腔崩解片。辅料包括崩解剂、填充剂、泡腾剂、助流剂、润滑剂、矫味剂等。湿法压片是先将主药和部分崩解剂、填充剂、矫味剂和粘接剂混合,过30-60目筛,在40-90℃下干燥2-10小时;然后与剩余的崩解剂、填充剂、矫味剂以及泡腾剂、助流剂、润滑剂混合均匀,压片得到口腔崩解片。上述制片的压力为2-15Mpa,所得口腔崩解片硬度为2~5kg,体外崩解时间为20-80秒。该纳米碳酸镧口腔崩解片充分考虑了药物作用机理,能极大限度发挥药物的疗效,降低患者的服药量,提高患者的顺应性。
The invention relates to a nanometer lanthanum carbonate orally disintegrating tablet and a preparation method thereof. The main drug and auxiliary materials are dried at 40-80°C for 2-4 hours by dry compression, passed through a 100-mesh sieve, and then compressed to obtain orally disintegrating tablets. Excipients include disintegrants, fillers, effervescent agents, glidants, lubricants, flavoring agents, etc. Wet tableting is to mix the main drug and some disintegrants, fillers, flavoring agents and binders, pass through a 30-60 mesh sieve, and dry at 40-90°C for 2-10 hours; then mix with the remaining The disintegrating agent, filler, flavoring agent, effervescent agent, glidant, and lubricant are mixed evenly, and compressed into tablets to obtain orally disintegrating tablets. The pressure of the above tablet making is 2-15Mpa, the obtained orally disintegrating tablet has a hardness of 2-5kg, and the disintegration time in vitro is 20-80 seconds. The nano-lanthanum carbonate orally disintegrating tablet fully considers the mechanism of drug action, can maximize the curative effect of the drug, reduce the dosage of the patient, and improve the compliance of the patient.
Description
技术领域 technical field
本发明属于纳米材料技术领域,以及药物科学领域。The invention belongs to the technical field of nanometer materials and the field of pharmaceutical science.
背景技术 Background technique
高磷酸血症是慢性肾衰的一种并发症,80%的肾透析病人患有此症。该症可能引起骨质病变,皮肤发痒,甚至皮肤溃疡等方面的疾病外,还会造成心血管系统的损害,有50%的患者因此而死亡。服用磷结合剂是目前治疗高血磷症的主要治疗手段。Hyperphosphatemia is a complication of chronic renal failure, 80% of renal dialysis patients suffer from this disease. The disease may cause bone lesions, skin itching, and even skin ulcers, etc., and also cause damage to the cardiovascular system, and 50% of patients will die as a result. Phosphate binders are currently the mainstay of treatment for hyperphosphatemia.
磷酸盐结合剂可以螯合食物中的磷,阻止胃肠道对磷的吸收。第一代磷结合剂是铝盐,它能有效降低慢性肾衰病人血清中的磷酸盐水平,但长期使用会导致痴呆和软骨病,因而其临床应用受到了限制。含钙的磷结合剂(如醋酸钙、碳酸钙)也能降低高磷酸血症病人的血清磷水平,但会增加高钙血和钙化的发生率,这种情况在使用维生素D的患者中尤为特出,且病人对此类药物的顺应性差。因此人们希望开发研制非铝、钙型磷结合剂。1998年GenzymeGenerals和GelTex雨家制药公司生產出Renagel片劑,这也是一种用来治療行血液透析的晚期腎病患者的高血磷症的药物。Renagel是一种聚合物树脂,它携带多个胺基可在小肠内质子化而带正电荷,通过离子交换和氢键与小肠中的磷酸根结合从而降低血磷。但Renagel能否有效抑制甲状旁腺增生和降低高PTH、对血钙的水平有无影响,这方面的实验数据还有限。Phosphate binders chelate phosphorus in food, preventing its absorption from the gastrointestinal tract. The first-generation phosphorus binders are aluminum salts, which can effectively reduce the serum phosphate level in patients with chronic renal failure, but long-term use can lead to dementia and osteomalacia, so its clinical application is limited. Calcium-containing phosphate binders (eg, calcium acetate, calcium carbonate) also reduce serum phosphorus levels in patients with hyperphosphatemia but increase the incidence of hypercalcemia and calcification, especially in patients taking vitamin D Outstanding, and the patient's compliance with such drugs is poor. Therefore, people hope to develop non-aluminum, calcium-type phosphorus binders. In 1998, Genzyme Generals and GelTex Yujia Pharmaceutical Company produced Renagel tablets, which is also a drug used to treat hyperphosphatemia in patients with end-stage renal disease undergoing hemodialysis. Renagel is a polymer resin that carries multiple amine groups that can be protonated in the small intestine to be positively charged. It combines with phosphate groups in the small intestine through ion exchange and hydrogen bonding to reduce blood phosphorus. But whether Renagel can effectively inhibit parathyroid hyperplasia and reduce high PTH, and whether it has any effect on blood calcium levels, the experimental data in this area are still limited.
镧(原子序数57,原子质量159)是一种对氧供体原子有强亲和力的稀有元素,镧盐能与碳氧化合物及磷酸盐类化合物结合产生水溶性小、不易透过生物膜的磷酸镧分子。作为一种非钙、非铝的磷结合剂,氯化镧、碳酸镧等具有与传统结合剂同样降低病人血清中的磷酸盐水平的作用,而且不会导致血清钙的升高和产生严重副作用,耐受性也较好;它将会成为新一代治疗高血磷症的药物。英国先令公司推出的碳酸镧药物Fosrenl是一种咀嚼片,于2004年上市。其中有效成分碳酸镧的粒径是影响药物疗效的关键,而先令公司并未涉及碳酸镧晶体粒径的大小。现有碳酸镧晶体颗粒尺度较大,因此比表面积小,导致吸附能力不高。Lanthanum (atomic number 57, atomic mass 159) is a rare element that has a strong affinity for oxygen donor atoms. Lanthanum salts can combine with carbon oxides and phosphate compounds to produce phosphoric acid that is less water-soluble and difficult to pass through biomembranes. Lanthanum molecule. As a non-calcium, non-aluminum phosphorus binder, lanthanum chloride, lanthanum carbonate, etc. have the same effect as traditional binders on reducing the phosphate level in the patient's serum, and will not lead to an increase in serum calcium and serious side effects , and better tolerance; it will become a new generation of drugs for the treatment of hyperphosphatemia. The lanthanum carbonate drug Fosrenl launched by the British Shilling Company is a chewable tablet that was launched in 2004. Among them, the particle size of the active ingredient lanthanum carbonate is the key to affect the curative effect of the drug, and Shilling Company did not involve the particle size of the lanthanum carbonate crystal. The existing lanthanum carbonate crystal particle size is large, so the specific surface area is small, resulting in low adsorption capacity.
发明内容 Contents of the invention
为了解决现有技术的不足,本发明提出一种纳米碳酸镧口腔崩解片及制备方法和纳米碳酸镧的制备方法。In order to solve the deficiencies of the prior art, the present invention proposes a nano-lanthanum carbonate orally disintegrating tablet, a preparation method thereof and a preparation method of the nano-lanthanum carbonate.
纳米碳酸镧口腔崩解片的制备方法:The preparation method of nanometer lanthanum carbonate orally disintegrating tablet:
1).配制制剂成分:1). Preparation ingredients:
碳酸镧纳米晶: 5-40份Lanthanum carbonate nanocrystals: 5-40 parts
崩解剂: 10-70份Disintegrant: 10-70 parts
填充剂: 15-60份Filler: 15-60 parts
矫味剂: 0-5份Flavoring agent: 0-5 parts
泡腾剂: 0-5份Effervescent agent: 0-5 parts
助流剂: 0-4份Glidant: 0-4 parts
润滑剂: 0-2份Lubricant: 0-2 parts
粘接剂: 0.5-3份;Adhesive: 0.5-3 parts;
采用干法压片和湿法压片两种技术制备纳米碳酸镧口腔崩解片。干法压片是将主药和辅料等在40-80℃下干燥2-4小时,过40-100目筛,然后压片得到口腔崩解片。辅料包括崩解剂、填充剂、泡腾剂、助流剂、润滑剂、矫味剂等。湿法压片是先将主药和部分崩解剂、填充剂、矫味剂和粘接剂混合,过30-60目筛,在40-90℃下干燥2-10小时;然后与剩余的崩解剂、填充剂、矫味剂以及泡腾剂、助流剂、润滑剂混合均匀,压片得到口腔崩解片。上述制片的压力为2-15Mpa,所得口腔崩解片硬度为2~5kg,体外崩解时间为20-80秒。Orally disintegrating tablets of nano-lanthanum carbonate were prepared by two techniques of dry compression and wet compression. Dry compression is to dry the main drug and auxiliary materials at 40-80°C for 2-4 hours, pass through a 40-100 mesh sieve, and then compress to obtain orally disintegrating tablets. Excipients include disintegrants, fillers, effervescent agents, glidants, lubricants, flavoring agents, etc. Wet tableting is to mix the main drug and some disintegrants, fillers, flavoring agents and binders, pass through a 30-60 mesh sieve, and dry at 40-90°C for 2-10 hours; then mix with the remaining The disintegrating agent, filler, flavoring agent, effervescent agent, glidant, and lubricant are mixed evenly, and compressed into tablets to obtain orally disintegrating tablets. The pressure of the above tablet making is 2-15Mpa, the obtained orally disintegrating tablet has a hardness of 2-5kg, and the disintegration time in vitro is 20-80 seconds.
所述崩解剂为交联羧甲基纤维素钠(cCMC-Na)、交联羧甲基淀粉钠(CMS-Na)、低取代羟丙纤维素(LSHPC)、交联聚乙烯吡咯烷酮(PPVP)或微晶纤维素(MCC)的一种以及上述两种或两种以上的上述聚合物的组合。The disintegrating agent is cross-linked carboxymethylcellulose sodium (cCMC-Na), cross-linked carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (LSHPC), cross-linked polyvinylpyrrolidone (PPVP ) or one of microcrystalline cellulose (MCC) and a combination of two or more of the above-mentioned polymers.
所述的崩解剂为交联羧甲基纤维素钠、交联羧甲基淀粉钠、低取代羟丙纤维素、交联聚乙烯吡咯烷酮或微晶纤维素的一种或两种以上的聚合物的组合。The disintegrating agent is one or more polymers of cross-linked carboxymethylcellulose sodium, cross-linked carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone or microcrystalline cellulose combination of things.
所述的填充剂为甘露醇、四丁醇、乳糖、蔗糖、木糖醇或山梨醇的一种或两种以上的聚合物的组合。The filler is one or a combination of two or more polymers of mannitol, tetrabutanol, lactose, sucrose, xylitol or sorbitol.
所述的矫味剂为薄荷醇、薄荷油、甘草、柠檬酸、酒石酸、肉桂或香精的一种或两种以上的聚合物的组合。The flavoring agent is one or more polymers of menthol, peppermint oil, licorice, citric acid, tartaric acid, cinnamon or essence.
所述的泡腾剂为碳酸氢钠。Described effervescent agent is sodium bicarbonate.
所述的助流剂为微粉硅胶。The glidant is micronized silica gel.
所述的润滑剂为硬脂酸镁或滑石粉。Described lubricant is magnesium stearate or talcum powder.
所述的粘接剂为聚维酮、聚乙二醇、予糊化淀粉、糊精或甲基纤维素的一种或两种以上的聚合物的组合。The binder is one or a combination of two or more polymers of povidone, polyethylene glycol, pregelatinized starch, dextrin or methylcellulose.
碳酸镧纳米晶可以选用已有的产品,当然也可以用我们发明的方法制备的碳酸镧纳米晶。The lanthanum carbonate nanocrystals can be selected from existing products, and of course the lanthanum carbonate nanocrystals prepared by the method we invented can also be used.
本发明制备的纳米碳酸镧采用如下方法制备:The nano lanthanum carbonate prepared by the present invention adopts following method to prepare:
1)配制0.1-10wt%稳定剂溶液和0.01-0.9mol/L镧化合物溶液,并将两种溶液混合均匀,静置10-30分钟,将配制好的0.01-1.2mol/L碳酸盐溶液加入到上述混合溶液中,控制成核温度5-30℃,搅拌反应5-20分钟;然后在10-50℃和搅拌下继续反应30min-4h,停止搅拌,加入浓度为0.1-5wt%表面活性剂溶液,然后放置10-60分钟;1) Prepare 0.1-10wt% stabilizer solution and 0.01-0.9mol/L lanthanum compound solution, mix the two solutions evenly, let stand for 10-30 minutes, and prepare 0.01-1.2mol/L carbonate solution Add it to the above mixed solution, control the nucleation temperature at 5-30°C, stir and react for 5-20 minutes; then continue to react at 10-50°C and stir for 30min-4h, stop stirring, and add a concentration of 0.1-5wt% surface active agent solution, and then left for 10-60 minutes;
2)将上述所得产物离心沉降10-40min,并用蒸馏水洗2-4遍;然后将固体干燥产物在马弗炉中培烧1-5小时,温度控制在150-400℃,升温速率为5-10℃/min;2) Centrifuge the product obtained above for 10-40 minutes, and wash it with distilled water 2-4 times; then burn the solid dry product in a muffle furnace for 1-5 hours, the temperature is controlled at 150-400 °C, and the heating rate is 5- 10℃/min;
所述的稳定剂为天然大分子明胶、壳聚糖、海藻酸盐、胶原、淀粉、纤维素及其衍生物;或聚乙烯醇、聚羟基丁酸酯及共聚物、聚酸酐、聚乙烯基吡咯烷酮、聚氧乙烯、聚乙二醇的合成的有机大分子;或木糖醇、山梨醇、甘露醇、丙三醇的多元醇;或蔗糖、乳糖、葡萄糖的多糖或单糖;他们一种或两种以上混合使用。The stabilizer is natural macromolecular gelatin, chitosan, alginate, collagen, starch, cellulose and derivatives thereof; or polyvinyl alcohol, polyhydroxybutyrate and copolymers, polyanhydrides, polyvinyl Synthetic organic macromolecules of pyrrolidone, polyoxyethylene, polyethylene glycol; or polyols of xylitol, sorbitol, mannitol, glycerol; or polysaccharides or monosaccharides of sucrose, lactose, glucose; one of them Or a mixture of two or more.
所述的镧化合物为氯化镧、硝酸镧、硫酸镧、醋酸镧或草酸镧。The lanthanum compound is lanthanum chloride, lanthanum nitrate, lanthanum sulfate, lanthanum acetate or lanthanum oxalate.
所述的碳酸盐为碳酸钠、碳酸钾、碳酸氨、碳酸氢纳、碳酸氢钾或碳酸氢氨。Described carbonate is sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate or ammonium bicarbonate.
所述的表面活性剂为十二烷基磺酸钠、司盘80、司盘60或吐温40。The surfactant is sodium dodecylsulfonate, Span 80, Span 60 or Tween 40.
本发明的特征之处在于:The present invention is characterized in that:
1.采用沉淀法可制备纳米尺度碳酸镧晶体,通过调节温度控制晶体的成核和晶体生长。1. Nanoscale lanthanum carbonate crystals can be prepared by the precipitation method, and the nucleation and crystal growth of the crystals can be controlled by adjusting the temperature.
2.通过调整加料方式控制晶体的大小。2. Control the crystal size by adjusting the feeding method.
3.利用稳定剂分子的吸附、稳定和空间限定作用,控制碳酸镧晶体的尺度和形状。3. Control the scale and shape of lanthanum carbonate crystals by utilizing the adsorption, stabilization and space confinement effects of stabilizer molecules.
4.加入表面活性剂可使晶体分散更均匀,防止团聚。4. Adding surfactant can make crystal dispersion more uniform and prevent agglomeration.
纳米碳酸镧口腔崩解片充分考虑了药物作用机理,能极大限度发挥药物的疗效,降低患者的服药量,提高患者的顺应性。Nano-lanthanum carbonate orally disintegrating tablets fully consider the mechanism of drug action, which can maximize the curative effect of the drug, reduce the dosage of the patient, and improve the compliance of the patient.
附图说明 Description of drawings
图1:纳米碳酸镧电镜扫描照片;Figure 1: Electron microscope scanning photo of nano-lanthanum carbonate;
图2:纳米碳酸镧电镜扫描照片局部放大图。Figure 2: Partial enlarged view of the scanning electron microscope photo of nano-lanthanum carbonate.
具体实施方式 Detailed ways
实例1Example 1
首先配制1wt%明胶溶液、0.3mol/L碳酸钠溶液、0.2mol/L氯化镧溶液待用,然后取出50ml氯化镧溶液,加入20ml明胶溶液,搅拌使之混合均匀。用冰/水混合物水浴控制温度为5℃,加入50ml碳酸钠溶液,搅拌反应10min,而后以3℃/min速度升温,直到30℃停止,在此温度下反应30min,然后加入1wt%的十二烷基磺酸钠0.2ml,并放置20min。将浊液放入离心分离机中分离30min(3000r/min下同),取出沉降物,用水洗3遍,将得到的沉降物置于坩埚中。将盛有产物的坩埚放入马弗炉中加热,升温速率为10℃/min,直到400℃,在此温度下焙烧1小时,然后自然冷却至室温,得到纳米碳酸镧晶体见附图1和2。First prepare 1wt% gelatin solution, 0.3mol/L sodium carbonate solution, and 0.2mol/L lanthanum chloride solution for use, then take out 50ml of lanthanum chloride solution, add 20ml of gelatin solution, and stir to make it evenly mixed. Use an ice/water mixture water bath to control the temperature at 5°C, add 50ml of sodium carbonate solution, stir for 10 minutes, then raise the temperature at a rate of 3°C/min until it stops at 30°C, react at this temperature for 30 minutes, and then add 1 wt% of dodecyl Sodium alkyl sulfonate 0.2ml, and left for 20min. Put the turbid liquid into a centrifuge for separation for 30 minutes (3000r/min, the same below), take out the sediment, wash with water 3 times, and place the obtained sediment in a crucible. Put the crucible containing the product into a muffle furnace and heat it at a rate of 10°C/min until 400°C, bake it at this temperature for 1 hour, and then cool it down to room temperature naturally to obtain nano-lanthanum carbonate crystals. See Figure 1 and Figure 1. 2.
实例2Example 2
首先配制0.1wt%聚氧乙烯溶液、0.06mol/L碳酸钾溶液、0.04mol/L硝酸镧溶液待用,然后取出50ml硝酸镧溶液,加入20ml聚乙二醇溶液,搅拌使之混合均匀。用冰/水混合物水浴控制温度为10℃,加入50ml碳酸钾溶液,搅拌反应15min,而后以5℃/min速度升温,直到30℃停止,并在此温度下反应50min,然后加入0.2ml浓度为0.1wt%的司盘80,并放置40min。将得到的乳浊液放入离心分离机中分离40min,取出沉降物,用水洗2遍,将得到的沉降物置于坩埚中。所坩埚放入马弗炉中焙烧,升温速率为5℃/min,直到300℃,在此温度下焙烧0.5小时,然后自然冷却至室温,得到纳米碳酸镧晶体。First prepare 0.1wt% polyoxyethylene solution, 0.06mol/L potassium carbonate solution, and 0.04mol/L lanthanum nitrate solution for use, then take out 50ml of lanthanum nitrate solution, add 20ml of polyethylene glycol solution, and stir to make it evenly mixed. Use an ice/water mixture water bath to control the temperature at 10°C, add 50ml of potassium carbonate solution, stir for 15min, then raise the temperature at a rate of 5°C/min until it stops at 30°C, and react at this temperature for 50min, then add 0.2ml of 0.1wt% Span 80, and leave it for 40min. Put the obtained emulsion into a centrifuge for separation for 40 minutes, take out the sediment, wash it twice with water, and place the obtained sediment in a crucible. The crucible was put into a muffle furnace and fired at a heating rate of 5°C/min until 300°C, fired at this temperature for 0.5 hour, and then naturally cooled to room temperature to obtain nano-lanthanum carbonate crystals.
实例3Example 3
首先配制10wt%丙三醇溶液、1.2mol/L碳酸氢氨溶液、0.9mol/L醋酸化镧溶液待用,然后取出100ml醋酸镧溶液,加入2ml丙三醇溶液,搅拌使之混合均匀。用冰/水混合物水浴控制温度为15℃,逐滴加入100ml碳酸氢氨溶液,20分钟加完,搅拌反应5min,而后以2℃/min速度升温,直到25℃停止,在此温度下反应70min,然后加入0.5ml浓度为5wt%的吐温40,并放置30min。将浊液放入离心分离机中分离20min,取出沉降物,用水洗4遍,将得到的沉降物置于坩埚中。将盛有产物的坩埚放入马弗炉中加热,升温速率为10℃/min,直到250℃,在此温度下焙烧1小时,然后自然冷却至室温,得到碳酸镧纳米晶体。First prepare 10wt% glycerol solution, 1.2mol/L ammonium bicarbonate solution, and 0.9mol/L lanthanum acetate solution for use, then take out 100ml lanthanum acetate solution, add 2ml glycerol solution, and stir to make it evenly mixed. Use an ice/water mixture water bath to control the temperature at 15°C, add 100ml of ammonium bicarbonate solution drop by drop, complete the addition in 20 minutes, stir and react for 5 minutes, then raise the temperature at a rate of 2°C/min until it stops at 25°C, and react at this temperature for 70 minutes , and then adding 0.5ml of Tween 40 with a concentration of 5wt%, and standing for 30min. Put the turbid liquid in a centrifuge for separation for 20 minutes, take out the sediment, wash it with water 4 times, and place the sediment in a crucible. The crucible containing the product was heated in a muffle furnace at a heating rate of 10°C/min until 250°C, baked at this temperature for 1 hour, and then cooled naturally to room temperature to obtain lanthanum carbonate nanocrystals.
实例4Example 4
首先配制2wt%乳糖溶液、0.6mol/L碳酸氢钠溶液、0.4mol/L硫酸化镧溶液待用,然后取出80ml碳酸镧溶液,加入3ml乳糖溶液,搅拌使之混合均匀。用冰/水混合物水浴控制温度为12℃,加入80ml碳酸氢钠溶液,搅拌反应5min,而后以3℃/min速度升温,直到30℃停止,在此温度下反应40min,然后加入0.5ml浓度为1wt%的吐温40,并放置30min。将浊液放入离心分离机中分离20min,取出沉降物,用水洗3遍,将得到的沉降物置于坩埚中。将盛有产物的坩埚放入马弗炉中加热,升温速率为5℃/min,直到150℃,在此温度下焙烧1小时,然后自然冷却至室温,得到碳酸镧纳米晶体。First prepare 2wt% lactose solution, 0.6mol/L sodium bicarbonate solution, and 0.4mol/L lanthanum sulfate solution for use, then take out 80ml of lanthanum carbonate solution, add 3ml of lactose solution, and stir to make it evenly mixed. Use an ice/water mixture water bath to control the temperature at 12°C, add 80ml of sodium bicarbonate solution, stir for 5 minutes, then raise the temperature at a rate of 3°C/min until it stops at 30°C, react at this temperature for 40 minutes, and then add 0.5ml of 1wt% Tween 40, and left for 30min. Put the turbid liquid in a centrifuge for separation for 20 minutes, take out the sediment, wash it with water 3 times, and place the obtained sediment in a crucible. The crucible containing the product was heated in a muffle furnace at a heating rate of 5°C/min until 150°C, baked at this temperature for 1 hour, and then cooled naturally to room temperature to obtain lanthanum carbonate nanocrystals.
实例5Example 5
首先配制1wt%聚氧乙烯溶液、2wt%聚乙烯醇、0.015mol/L碳酸氢钠溶液、0.01mol/L硫酸化镧溶液待用,然后取出100ml碳酸镧溶液,加入3ml聚氧乙烯溶液和3ml聚乙烯醇溶液,搅拌使之混合均匀。用水浴控制温度为30℃,加入100ml碳酸氢钠溶液,搅拌反应20min,而后以3℃/min速度升温,直到50℃停止,在此温度下反应40min,然后加入0.5ml浓度为1wt%的吐温40,并放置30min。将浊液放入离心分离机中分离20min,取出沉降物,用水洗3遍,将得到的沉降物置于坩埚中。将盛有产物的坩埚放入马弗炉中加热,升温速率为5℃/min,直到300℃,在此温度下焙烧1小时,然后自然冷却至室温,得到碳酸镧纳米晶体。First prepare 1wt% polyoxyethylene solution, 2wt% polyvinyl alcohol, 0.015mol/L sodium bicarbonate solution, 0.01mol/L lanthanum sulfate solution for use, then take out 100ml lanthanum carbonate solution, add 3ml polyoxyethylene solution and 3ml Polyvinyl alcohol solution, stir to make it evenly mixed. Control the temperature with a water bath to 30°C, add 100ml of sodium bicarbonate solution, stir and react for 20 minutes, then raise the temperature at a rate of 3°C/min until it stops at 50°C, react at this temperature for 40 minutes, and then add 0.5ml of 1 wt% spitan Temperature 40, and place for 30min. Put the turbid liquid in a centrifuge for separation for 20 minutes, take out the sediment, wash it with water 3 times, and place the obtained sediment in a crucible. The crucible containing the product was heated in a muffle furnace at a heating rate of 5°C/min until 300°C, baked at this temperature for 1 hour, and then cooled naturally to room temperature to obtain lanthanum carbonate nanocrystals.
实例6Example 6
首先配制0.5wt%明胶溶液、0.1wt%聚氧乙烯溶液、1wt%山梨醇、0.6mol/L碳酸钠溶液、0.4mol/L氯化镧溶液待用,然后取出50ml氯化镧溶液,加入20ml明胶、聚氧乙烯、山梨醇溶液,搅拌使之混合均匀。用冰/水混合物水浴控制温度为12℃,加入50ml碳酸钠溶液,搅拌反应15min,而后以3℃/min速度升温,直到30℃停止,在此温度下反应30min,然后加入1wt%的聚乙烯基吡咯烷酮0.1ml,并放置20min。将浊液放入离心分离机中分离30min(3000r/min下同),取出沉降物,用水洗3遍,将得到的沉降物置于坩埚中。将盛有产物的坩埚放入马弗炉中加热,升温速率为14℃/min,直到400℃,在此温度下焙烧1小时,然后自然冷却至室温,得到纳米碳酸镧晶体First prepare 0.5wt% gelatin solution, 0.1wt% polyoxyethylene solution, 1wt% sorbitol, 0.6mol/L sodium carbonate solution, 0.4mol/L lanthanum chloride solution for use, then take out 50ml lanthanum chloride solution, add 20ml Gelatin, polyoxyethylene, sorbitol solution, stir to make it evenly mixed. Use an ice/water mixture water bath to control the temperature at 12°C, add 50ml of sodium carbonate solution, stir for 15 minutes, then raise the temperature at a rate of 3°C/min until it stops at 30°C, react at this temperature for 30 minutes, and then add 1wt% polyethylene Base pyrrolidone 0.1ml, and left for 20min. Put the turbid liquid into a centrifuge for separation for 30 minutes (3000r/min, the same below), take out the sediment, wash with water 3 times, and place the obtained sediment in a crucible. Put the crucible containing the product into a muffle furnace and heat it at a rate of 14°C/min until 400°C, bake it at this temperature for 1 hour, and then cool it naturally to room temperature to obtain nano-lanthanum carbonate crystals
实例7Example 7
取12份上述制得的实例2中碳酸镧纳米晶体与38份甘露醇充分混合,然后与35份60℃下干燥3小时的微晶纤维素、3份PPVP、6份LSHPC混合均匀,并过100目筛,然后加入1份碳酸氢钠、2份微粉硅胶、1.5份硬脂酸镁、1份枸橼酸和0.5份橘子香精,并混合均匀,然后在5Mpa压力下压片,得到口腔崩解片。片硬度为3kg,体外崩解时限为53s。Get 12 parts of lanthanum carbonate nanocrystals and 38 parts of mannitol in the example 2 that above-mentioned make fully mix, then mix with 35 parts of microcrystalline cellulose, 3 parts of PPVP, 6 parts of LSHPC dried at 60 ℃ for 3 hours, and pass 100-mesh sieve, then add 1 part of sodium bicarbonate, 2 parts of micropowdered silica gel, 1.5 parts of magnesium stearate, 1 part of citric acid and 0.5 part of orange essence, mix well, and then compress the tablet under a pressure of 5Mpa to obtain oral disintegration solution piece. The tablet hardness is 3kg, and the in vitro disintegration time limit is 53s.
实例8Example 8
取7份上述制得的碳酸镧纳米晶体与24份木糖醇、15乳糖充分混合,然后与28份60℃下干燥3小时的微晶纤维素、11份LSHPC混合均匀,并过80目筛,然后加入5份碳酸氢钠、3份微粉硅胶、3份滑石粉、3份柠檬酸和1份甘草,并混合均匀,然后在10Mpa压力下压片,得到口腔崩解片。片硬度为5kg,体外崩解时限为75s。Get 7 parts of lanthanum carbonate nanocrystals prepared above and fully mix them with 24 parts of xylitol and 15 parts of lactose, then mix them evenly with 28 parts of microcrystalline cellulose dried at 60°C for 3 hours, and 11 parts of LSHPC, and pass through an 80-mesh sieve , then add 5 parts of sodium bicarbonate, 3 parts of micropowder silica gel, 3 parts of talcum powder, 3 parts of citric acid and 1 part of licorice, mix well, and then compress under a pressure of 10Mpa to obtain orally disintegrating tablets. The tablet hardness is 5kg, and the in vitro disintegration time limit is 75s.
实例9Example 9
取10份上述制得的碳酸镧纳米晶体与23份四丁醇、10乳糖充分混合,然后与36份60℃下干燥5小时的微晶纤维素、14份低取代羟丙纤维素混合均匀,并过80目筛,然后加入2份碳酸氢钠、2份微粉硅胶、1份硬脂酸镁、1份柠檬酸和1份甘草,并混合均匀,然后在7Mpa压力下压片,得到口腔崩解片。片硬度为4kg,体外崩解时限为15sGet 10 parts of above-mentioned prepared lanthanum carbonate nanocrystals and fully mix with 23 parts of tetrabutanol and 10 parts of lactose, then mix evenly with 36 parts of microcrystalline cellulose dried at 60° C. for 5 hours, and 14 parts of low-substituted hydroxypropyl cellulose, And pass through 80 mesh sieve, then add 2 parts of sodium bicarbonate, 2 parts of micropowder silica gel, 1 part of magnesium stearate, 1 part of citric acid and 1 part of licorice, mix well, and then compress under 7Mpa pressure to obtain oral disintegration solution piece. The tablet hardness is 4kg, and the in vitro disintegration time limit is 15s
实例10Example 10
取19份上述制得的碳酸镧纳米晶体与14份甘露醇、5份山梨醇、2份蔗糖充分混合,然后与42份60℃下干燥3小时的微晶纤维素、10份交联羧甲基纤维素钠(cCMC-Na)、2份交联羧甲基淀粉钠(CMS-Na)混合均匀,并过100目筛,然后加入1.5份碳酸氢钠、2份微粉硅胶、0.5份硬脂酸镁、1份枸橼酸和1份薄荷醇,并混合均匀,然后在3Mpa压力下压片,得到口腔崩解片。片硬度为3kg,体外崩解时限为38s。Get 19 parts of the lanthanum carbonate nanocrystals prepared above and fully mix them with 14 parts of mannitol, 5 parts of sorbitol, and 2 parts of sucrose, then mix them with 42 parts of microcrystalline cellulose dried at 60°C for 3 hours, 10 parts of croscarmellose Sodium cellulose cellulose (cCMC-Na), 2 parts of croscarmellose sodium starch (CMS-Na) were mixed evenly, and passed through a 100-mesh sieve, and then 1.5 parts of sodium bicarbonate, 2 parts of micropowdered silica gel, 0.5 part of stearin Magnesium acid, 1 part of citric acid and 1 part of menthol, and mixed uniformly, and then compressed under a pressure of 3Mpa to obtain orally disintegrating tablets. The tablet hardness is 3kg, and the in vitro disintegration time limit is 38s.
实例11Example 11
取22份上述制得的碳酸镧纳米晶体与25份木糖醇、16乳糖充分混合,然后与37份60℃下干燥3小时的微晶纤维素混合均匀,并过100目筛,并混合均匀,然后在10Mpa压力下压片,得到口腔崩解片。片硬度为5kg,体外崩解时限为83s。Get 22 parts of the lanthanum carbonate nanocrystals prepared above and fully mix them with 25 parts of xylitol and 16 parts of lactose, then mix them evenly with 37 parts of microcrystalline cellulose dried at 60°C for 3 hours, pass through a 100-mesh sieve, and mix them evenly , and then compressed under a pressure of 10Mpa to obtain orally disintegrating tablets. The tablet hardness is 5kg, and the in vitro disintegration time limit is 83s.
实例12Example 12
取16份上述制得的碳酸镧纳米晶体与24份木糖醇、21乳糖充分混合,然后与26份60℃下干燥4小时的微晶纤维素、10份LSHPC混合均匀,并过80目筛,然后加入2份微粉硅胶、1份滑石粉,并混合均匀,然后在10Mpa压力下压片,得到口腔崩解片。片硬度为5kg,体外崩解时限为46s。Get 16 parts of the lanthanum carbonate nanocrystals prepared above and fully mix them with 24 parts of xylitol and 21 parts of lactose, then mix them evenly with 26 parts of microcrystalline cellulose dried at 60°C for 4 hours, and 10 parts of LSHPC, and pass through an 80-mesh sieve , and then add 2 parts of micropowdered silica gel and 1 part of talc powder, mix well, and then compress the tablet under a pressure of 10Mpa to obtain an orally disintegrating tablet. The tablet hardness is 5kg, and the in vitro disintegration time limit is 46s.
实例13Example 13
取20份碳酸镧(威海佰德信新材料有限公司生产)与20份木糖醇、24蔗糖充分混合,然后与34份60℃下干燥5小时的微晶纤维素混合均匀,并过80目筛,然后加入1份微粉硅胶、1份滑石粉,并混合均匀,然后在10Mpa压力下压片,得到口腔崩解片。片硬度为4kg,体外崩解时限为59s。Get 20 parts of lanthanum carbonate (produced by Weihai Baidexin New Material Co., Ltd.), fully mix with 20 parts of xylitol and 24 parts of sucrose, then mix evenly with 34 parts of microcrystalline cellulose dried at 60°C for 5 hours, and pass through 80 mesh Sieve, then add 1 part of micropowder silica gel and 1 part of talc powder, mix well, and then compress the tablet under a pressure of 10 MPa to obtain an orally disintegrating tablet. The tablet hardness is 4kg, and the in vitro disintegration time limit is 59s.
实例14Example 14
取10份上述制得的碳酸镧纳米晶体与10份甘露醇、10份微晶纤维素、1份蔗糖、3份PPVP、0.5枸橼酸和5份聚维酮乙醇-水溶液(浓度为10wt%)充分混合均匀,过40目筛,在60℃下干燥4小时;然后与28份60℃下干燥3小时的微晶纤维素、12份LSHPC、1份PPVP、15份甘露醇、2份乳糖混合均匀,并过80目筛;然后加入1份碳酸氢钠、2份微粉硅胶、2份硬脂酸镁、1份枸橼酸和1份薄荷醇,并混合均匀,然后在5Mpa压力下压片,得到口腔崩解片。片硬度为3.5kg,体外崩解时限为58s。Get 10 parts of above-mentioned lanthanum carbonate nanocrystals and 10 parts of mannitol, 10 parts of microcrystalline cellulose, 1 part of sucrose, 3 parts of PPVP, 0.5 parts of citric acid and 5 parts of povidone ethanol-water solution (concentration is 10wt% ) were thoroughly mixed, passed through a 40-mesh sieve, and dried at 60°C for 4 hours; then mixed with 28 parts of microcrystalline cellulose dried at 60°C for 3 hours, 12 parts of LSHPC, 1 part of PPVP, 15 parts of mannitol, and 2 parts of lactose Mix well and pass through an 80-mesh sieve; then add 1 part of sodium bicarbonate, 2 parts of micropowdered silica gel, 2 parts of magnesium stearate, 1 part of citric acid and 1 part of menthol, mix well, and then press under a pressure of 5Mpa tablets to obtain orally disintegrating tablets. The tablet hardness is 3.5kg, and the in vitro disintegration time limit is 58s.
实例15Example 15
取15份上述制得的碳酸镧纳米晶体与14份甘露醇、12份微晶纤维素、1份蔗糖、5份LSHPC、1份交联羧甲基淀粉钠(CMS-Na)、0.5柠檬酸和1份PEG、2份糊精(浓度为25wt%的水溶液)充分混合均匀,过40目筛,在50℃下干燥6小时;然后与24份60℃下干燥3小时的微晶纤维素、7份LSHPC、3份PPVP、10份木糖醇、2份乳糖混合均匀,并过100目筛;然后加入0.5份碳酸氢钠、1.5份微粉硅胶、1份硬脂酸镁、0.5柠檬酸和0.5菠萝香精,并混合均匀,然后在4Mpa压力下压片,得到口腔崩解片。片硬度为3kg,体外崩解时限为49s。Get 15 parts of above-mentioned lanthanum carbonate nanocrystals and 14 parts of mannitol, 12 parts of microcrystalline cellulose, 1 part of sucrose, 5 parts of LSHPC, 1 part of croscarmellose sodium starch (CMS-Na), 0.5 parts of citric acid Mix well with 1 part of PEG and 2 parts of dextrin (aqueous solution with a concentration of 25wt%), pass through a 40-mesh sieve, and dry at 50°C for 6 hours; then dry with 24 parts of microcrystalline cellulose, Mix 7 parts of LSHPC, 3 parts of PPVP, 10 parts of xylitol, and 2 parts of lactose evenly, and pass through a 100-mesh sieve; then add 0.5 parts of sodium bicarbonate, 1.5 parts of micronized silica gel, 1 part of magnesium stearate, 0.5 parts of citric acid and 0.5 pineapple flavor, and mixed evenly, then compressed under 4Mpa pressure to obtain orally disintegrating tablets. The tablet hardness is 3kg, and the in vitro disintegration time limit is 49s.
实例16Example 16
取40份上述制得的碳酸镧纳米晶体与20份甘露醇、16份微晶纤维素充分混合均匀,过40目筛,在60℃下干燥5小时;然后与21份60℃下干燥3小时的微晶纤维素、3份聚乙二醇并过100目筛;混合均匀,然后在10Mpa压力下压片,得到口腔崩解片。片硬度为5kg,体外崩解时限为80s。Take 40 parts of lanthanum carbonate nanocrystals prepared above, mix well with 20 parts of mannitol, and 16 parts of microcrystalline cellulose, pass through a 40-mesh sieve, and dry at 60°C for 5 hours; then dry with 21 parts of 60°C for 3 hours microcrystalline cellulose, 3 parts of polyethylene glycol and passed through a 100-mesh sieve; mixed evenly, and then compressed under a pressure of 10Mpa to obtain an orally disintegrating tablet. The tablet hardness is 5kg, and the in vitro disintegration time limit is 80s.
实例17Example 17
取6份上述制得的碳酸镧纳米晶体与5份甘露醇、5份山梨醇、10份微晶纤维素、8交联羧甲基淀粉钠、5分低取代羟丙纤维素、1份蔗糖、2份PPVP、0.5柠檬酸和3份聚维酮乙醇-水溶液(浓度为10wt%)充分混合均匀,过40目筛,在60℃下干燥3小时;然后与20份60℃下干燥3小时的微晶纤维素、9份LSHPC、1份PPVP、15份甘露醇、1.5份乳糖混合均匀,并过80目筛;然后加入1份碳酸氢钠、0.5份微粉硅胶、4份硬脂酸镁、1.5份柠檬酸和1份薄荷醇,并混合均匀,然后在5Mpa压力下压片,得到口腔崩解片。片硬度为3.5kg,体外崩解时限为58s。Get 6 parts of above-mentioned lanthanum carbonate nanocrystals and 5 parts of mannitol, 5 parts of sorbitol, 10 parts of microcrystalline cellulose, 8 parts of croscarmellose sodium, 5 parts of low-substituted hydroxypropyl cellulose, and 1 part of sucrose , 2 parts of PPVP, 0.5 citric acid and 3 parts of povidone ethanol-water solution (concentration is 10wt%) are fully mixed, passed through a 40-mesh sieve, and dried at 60°C for 3 hours; then dried with 20 parts of 60°C for 3 hours Microcrystalline cellulose, 9 parts of LSHPC, 1 part of PPVP, 15 parts of mannitol, and 1.5 parts of lactose were mixed evenly and passed through an 80-mesh sieve; then 1 part of sodium bicarbonate, 0.5 parts of micropowder silica gel, and 4 parts of magnesium stearate were added , 1.5 parts of citric acid and 1 part of menthol, and mix uniformly, then compress the tablet under a pressure of 5Mpa to obtain an orally disintegrating tablet. The tablet hardness is 3.5kg, and the in vitro disintegration time limit is 58s.
本发明并不局限于实施例中所描述的技术,它的描述是说明性的,并非限制性的,本发明的权限由权利要求所限定,基于本技术领域人员依据本发明所能够变化、重组等方法得到的与本发明相关的技术,都在本发明的保护范围之内。The present invention is not limited to the technology described in the embodiment, its description is illustrative, not restrictive, the authority of the present invention is defined by the claims, based on those skilled in the art can change and reorganize according to the present invention The technologies related to the present invention obtained by such methods are all within the protection scope of the present invention.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100138360A CN101077338B (en) | 2006-05-24 | 2006-05-24 | Nano lanthanum carbonate and orally disintegrating tablet and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100138360A CN101077338B (en) | 2006-05-24 | 2006-05-24 | Nano lanthanum carbonate and orally disintegrating tablet and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101077338A CN101077338A (en) | 2007-11-28 |
| CN101077338B true CN101077338B (en) | 2012-06-20 |
Family
ID=38905110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100138360A Expired - Fee Related CN101077338B (en) | 2006-05-24 | 2006-05-24 | Nano lanthanum carbonate and orally disintegrating tablet and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101077338B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969497A (en) * | 2018-10-12 | 2018-12-11 | 沈阳华泰药物研究有限公司 | A kind of lanthanum carbonate tablet composition and preparation method thereof |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011051968A2 (en) * | 2009-10-26 | 2011-05-05 | Alkem Laboratories Ltd. | Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof |
| CA3224506A1 (en) * | 2010-05-12 | 2011-11-17 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
| CN103145170A (en) * | 2013-03-27 | 2013-06-12 | 吉首大学 | Method for preparing lanthanum carbonate by reacting supercritical carbon dioxide and lanthanum oxide |
| CN104473963B (en) * | 2014-12-24 | 2017-10-10 | 厦门科明达科技有限公司 | The preparation method of rare earth chemistry medicine lanthanum carbonate chewable tablets |
| CN105568262B (en) * | 2015-12-28 | 2017-12-19 | 重庆大学 | A kind of preparation method of wear-resistant, damage resistant, corrosion resistant metal surface film layer |
| CN107213126B (en) * | 2017-05-17 | 2020-06-23 | 西安棣加生物科技有限公司 | Method for preparing oral rapidly disintegrating tablet for treating hyperphosphatemia by 3D printing technology |
| JP2020033303A (en) * | 2018-08-30 | 2020-03-05 | コーアイセイ株式会社 | Orally quick disintegrating tablet containing lanthanum carbonate and being stable |
| CN111620363A (en) * | 2020-06-13 | 2020-09-04 | 南京卡文迪许生物工程技术有限公司 | Preparation method of lanthanum carbonate tetrahydrate and product thereof |
| CN112315916B (en) * | 2020-11-12 | 2021-07-06 | 东莞市金美济药业有限公司 | Traditional Chinese medicine granules for treating osteoarthritis and preparation method thereof |
| CN115813867B (en) * | 2022-12-01 | 2024-05-24 | 山东齐都药业有限公司 | Lanthanum carbonate freeze-dried tablet and preparation method thereof |
| CN116036037B (en) * | 2023-02-06 | 2025-03-07 | 青岛润昕德生物医药有限公司 | Lanthanum polystyrene sulfonate sheet and preparation method thereof |
| CN119454898B (en) * | 2025-01-14 | 2025-07-08 | 佛山市口腔医院(佛山市牙病防治指导中心) | A sedation-maintaining agent administered via oral mucosa and a preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1184428A (en) * | 1995-03-25 | 1998-06-10 | 约翰逊马西有限公司 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
| CN1706372A (en) * | 2005-05-24 | 2005-12-14 | 中国人民解放军第二军医大学 | Sodium ferulate orally disintegrating tablet and preparation method thereof |
-
2006
- 2006-05-24 CN CN2006100138360A patent/CN101077338B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1184428A (en) * | 1995-03-25 | 1998-06-10 | 约翰逊马西有限公司 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
| CN1706372A (en) * | 2005-05-24 | 2005-12-14 | 中国人民解放军第二军医大学 | Sodium ferulate orally disintegrating tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969497A (en) * | 2018-10-12 | 2018-12-11 | 沈阳华泰药物研究有限公司 | A kind of lanthanum carbonate tablet composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101077338A (en) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101077338B (en) | Nano lanthanum carbonate and orally disintegrating tablet and preparation method | |
| JP5209492B2 (en) | Pharmaceutical formulations for the production of fast-disintegrating tablets | |
| KR101565621B1 (en) | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose | |
| WO2005037319A1 (en) | Composition for tablet rapidly disintegrable in mouth | |
| CN105816437A (en) | A pharmaceutical preparation of palbociclib and its preparation method | |
| JP5342028B2 (en) | Orally disintegrating tablets | |
| JPWO2007029376A1 (en) | Orally rapidly disintegrating tablets | |
| CN102716097A (en) | Method for controlling medicament release rate of orally disintegrating tablet | |
| WO2022012172A1 (en) | Oral sustained-release composition for insoluble drug, and preparation method thereof | |
| WO2020249001A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| JPWO2011118453A1 (en) | Solid preparation | |
| WO2019151405A1 (en) | Tablets and method for producing same | |
| JP2012515723A (en) | Disintegrating preparation of lanthanum carbonate | |
| WO2024140984A1 (en) | Controlled release tablet of loxoprofen sodium, preparation method, and use | |
| CN101564402A (en) | Rehabilitation new dispersing tablet and preparation method thereof | |
| JP6623753B2 (en) | Orally disintegrating tablets containing lanthanum carbonate | |
| CN103393612B (en) | Preparation method for enalapril maleate orally disintegrating tablets | |
| CN102846573B (en) | Silibinin double-layer slow-release tablets and preparation method thereof | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN116036079A (en) | Pharmaceutical composition of compound and preparation method thereof | |
| JPH04243828A (en) | Solid oral ifosfamide pharmaceutical composition and method for producing the same | |
| KR101093447B1 (en) | Pentoxifylline sustained-release composition and preparation method | |
| CN103070842B (en) | Preparation method of miglitol sustained release tablet | |
| WO2018192000A1 (en) | Osmotic pump tablet of perindopril and salt thereof and preparation method of same | |
| JP2018193349A (en) | Orally disintegrating tablet containing lanthanum carbonate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120620 Termination date: 20130524 |